Oncology and Hematology - Global Oncology Academy

385-400 of 743

Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Project Oncology®
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Namrata Vijayvergia, MD
- Namrata Vijayvergia, MD
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Project Oncology®
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
MinuteCE®
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Scott Kopetz, MD, PhD; Cathy Eng, MD, FACP
1.00 program credit
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 program credit
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
MinuteCE®
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
Scott Kopetz, MD, PhD; Cathy Eng, MD, FACP
1.00 program credit
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 program credit
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
MinuteCE®
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
Scott Kopetz, MD, PhD; Cathy Eng, MD, FACP
1.00 program credit
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 program credit
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
CME/CE
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Kevin Kalinsky MD, MS; Komal Jhaveri, MD, FACP
0.50 credits
- Kevin Kalinsky MD, MS
- Komal Jhaveri, MD, FACP
0.50 credits
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Clinician's Roundtable
Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Targeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Targeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Clinician's Roundtable
Targeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Project Oncology®
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Charles Turck, PharmD, BCPS, BCCCP; Matthew Lunning, DO, FACP
- Charles Turck, PharmD, BCPS, BCCCP
- Matthew Lunning, DO, FACP
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Project Oncology®
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Ryan Quigley; David F. McDermott, MD
- Ryan Quigley
- David F. McDermott, MD
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Project Oncology®
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Aline Fares, MD
- Aline Fares, MD
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Project Oncology®
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Jorge Nieva, MD
- Jorge Nieva, MD
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Project Oncology®
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
On the Frontlines of Prostate Cancer
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
Wayne Kuang, MD; William Oh, MD
- Wayne Kuang, MD
- William Oh, MD
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Project Oncology®
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Jorge Nieva, MD
- Jorge Nieva, MD

25/11